electroCore, Inc.
NASDAQ:ECOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
electroCore, Inc.
NASDAQ:ECOR
|
US |
|
Q
|
Qinhuangdao Tianqin Equipment Manufacturing Co Ltd
SZSE:300922
|
CN |
|
Caesars Entertainment Inc
NASDAQ:CZR
|
US |
|
H
|
HUHUTECH International Group Inc
NASDAQ:HUHU
|
CN |
|
F
|
Fibocom Wireless Inc
SZSE:300638
|
CN |
|
Jilin Jian Yisheng Pharmaceutical Co Ltd
SZSE:002566
|
CN |
|
Sequans Communications SA
NYSE:SQNS
|
FR |
|
A
|
Anton Oilfield Services Group
HKEX:3337
|
CN |
|
Boyaa Interactive International Ltd
HKEX:434
|
CN |
|
Ackermans & Van Haaren NV
OTC:AVHNY
|
BE |
|
Nyxoah SA
XBRU:NYXH
|
BE |
|
C
|
Cecep Costin New Materials Group Ltd
HKEX:2228
|
HK |
|
H
|
Hanjia Design Croup Co Ltd
SZSE:300746
|
CN |
|
Desktop SA
BOVESPA:DESK3
|
BR |
|
Charles River Laboratories International Inc
NYSE:CRL
|
US |
|
A
|
Alarko Gayrimenkul Yatirim Ortakligi AS
IST:ALGYO.E
|
TR |
|
N
|
Norse Atlantic ASA
OSE:NORSE
|
NO |
|
Jayaswal Neco Industries Ltd
NSE:JAYNECOIND
|
IN |
|
Dream Impact Trust
TSX:MPCT.UN
|
CA |
|
BYD Co Ltd
SZSE:002594
|
CN |
|
Electro Aco Altona SA
BOVESPA:EALT4
|
BR |
|
N
|
Norte Grande SA
SGO:NORTEGRAN
|
CL |
electroCore, Inc.
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
